Navigating Prior Authorizations in Dermatology

Explore the challenges and solutions to the rising costs of dermatologic medications and the impact of prior authorization on patient care. Learn about the driving factors behind the increasing prices of biologics and common dermatologic drugs, and the efforts to improve the prior authorization process for healthcare providers and patients.

What are Biosimilars?

Biologic products are drugs that have regulation by the United States Food and Drug Administration. They have utility to diagnose, prevent, treat and cure medical diseases and conditions. They are usually large and complex molecules and are harder to characterize than small molecule drugs. Common and familiar biologics include etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), […]